Expanded Access of Cabozantinib in Medullary Thyroid Cancer

Summary

The objective of this study is to provide access to cabozantinib for eligible subjects with medullary thyroid cancer (MTC) pending approval of Exelixis' New Drug Application (NDA) by the FDA and commercial availability of cabozantinib.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications